Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2013; 19(43): 7652-7660
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7652
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7652
Ref. | Year | Country | Age (SD or range) | Received no previous CD treatment (% of EEN group) | Number of participants | % that achieved remission (intention to treat) | Significant difference (P value) | Remission criteria | Number that did not complete EEN intervention, n (%) | % that achieved remission (treatment completed) | ||||
EEN | CS | EEN | CS | Formula un-palatable | Other reason | EEN | CS | |||||||
Engelman et al[19] | 1993 | England | 23-54 | Not stated | 7 | 4 | 100% | 100% | NS | HBI < 6.0 | 0 (0) | 0 | 100% | 100% |
1Gassull et al[27] | 2002 | Europe | 31.3 (3.3) | 50% | 20 | 19 | 20% | 79% | 0.0005 | VHAI < 120 | 5 (25) | 0 | 27% | 79% |
2Gassull et al[27] | 2002 | Europe | 30.8 (4.1) | 43.50% | 23 | 19 | 52% | 79% | NS | VHAI < 120 | 4 (17) | 0 | 63% | 79% |
González-Huix et al[23] | 1993 | Spain | 31.1 (4.1) | 47% | 15 | 17 | 8% | 88% | NS | VHAI < 120 | 0 (0) | 0 | 80% | 88% |
Gorard et al[21] | 1993 | England | 31.6 (3.0) | 50% | 22 | 20 | 45% | 85% | < 0.05 | HBI - remission not defined , mean < 2 | 9 (41) | 2 | 91% | 89% |
Lindor et al[25] | 1992 | United States | 34.7 (26-64) | 33% | 9 | 10 | 50% | 33% | NS | CDAI decrease > 100 points | 3 (33) | 1 | 60% | 63% |
Lochs et al[28] | 1991 | Europe | 27.5 (1.5) | Not stated | 55 | 52 | 53% | 79% | < 0.01 | CDAI decrease > 100 points or > 40% | 7 (13) | 0 | 60% | 85% |
Malchow et al[29] | 1990 | Europe | 30.1 (11.5) | 20% | 51 | 44 | 41% | 71% | < 0.05 | CDAI decrease > 100 points or > 40% | 20 (39) | 0 | 71% | 91% |
Mantzaris et al[20] | 1996 | Greece | Not stated | 20% | 10 | 10 | 40% | 70% | NS | CDAI < 150 or decrease > 100 points | 0 (0) | 0 | 40% | 70% |
Okada et al[26] | 1990 | Japan | 21.0 (3.3) | 100% | 10 | 10 | 80% | 30% | < 0.01 | HBI < 1 | 0 (0) | 0 | 80% | 30% |
O'Moráin et al[22] | 1984 | England | 31.9 (15-60) | 100% | 11 | 10 | 82% | 80% | NS | HBI - remission not defined. Mean < 3 | 2 (18) | 0 | 100% | 100% |
Zoli et al[24] | 1997 | Italy | 33.5 (15.9) | Not stated | 12 | 10 | 67% | 50% | NS | HBI < 3 | 1 (8) | 1 | 80% | 50% |
Ref. | Nutritional product | Type of feed | Duration of EEN (wk) | Calorie density (kcal/mL) | Nutritional composition (% TE) | Mode of delivery | Calorie intake per day |
Engelman et al[19] | Peptamen | Peptide based elemental | 2 | 1 | Pro 16, CHO 51, Fat 33 | Orally | 30-35 kcal/kg per day |
Gassull et al[27] | High oleic acid | Polymeric (powder) | 4 | 1 | Pro 22, CHO 46, Fat 32 | Orally and NGT | Not stated |
Gassull et al[27] | High linoleic acid | Polymeric (powder) | 4 | 1 | Pro 22, CHO 46, Fat 32 | Orally and NGT | Not stated |
González-Huix et al[23] | Edanec HN | Polymeric | 4 | 1 | Pro 22, CHO 46, Fat 32 | NGT | Not stated |
Gorard et al[21] | Vivonex TEN | Elemental | 4 | 1 | Pro 15, CHO 82, Fat 3 | Orally, or NGT | 2100 kcal per day |
Lindor et al[25] | Vital HN | Peptide based elemental | 4 | 1 | Pro 17, CHO 74, Fat 9 | Orally | 40 kcal/kg per day |
Lochs et al[28] | Peptisorb | Peptide based elemental | 4-6 | 1 | Pro 16, CHO 69, Fat 15 | NGT or NDT | 35 kcal/kg per day |
Malchow et al[29] | Survimed | Peptide based elemental | 3-6 | 1 | Pro 14, CHO 76, Fat 10 | Orally | 33 kcal/kg per day |
Mantzaris et al[20] | Nutrison HE | Polymeric | 4 | 1.5 | Pro 16, CHO 49, Fat 35 | NDT | 2250 kcal per day |
Okada et al[26] | Elental | Elemental | 6 | 1 | Pro 19, CHO 81, Fat 1 | NDT | 40-60 kcal/kg per day |
O'Moráin et al[22] | Vivonex | Elemental | 4 | 1 | Pro 15, CHO 82, Fat 3 | Orally, or NGT | 40-60 kcal/kg per day |
Zoli et al[24] | Peptamen | Peptide based elemental | 2 | 1 | Pro 16, CHO 51, Fat 33 | Orally | Not stated |
- Citation: Wall CL, Day AS, Gearry RB. Use of exclusive enteral nutrition in adults with Crohn’s disease: A review. World J Gastroenterol 2013; 19(43): 7652-7660
- URL: https://www.wjgnet.com/1007-9327/full/v19/i43/7652.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i43.7652